K Malottki
Sanofi (France)(FR)Sanofi (United Kingdom)(GB)
Publications by Year
Research Areas
Health Systems, Economic Evaluations, Quality of Life, Rheumatoid Arthritis Research and Therapies, Meta-analysis and systematic reviews, Psoriasis: Treatment and Pathogenesis, Statistical Methods in Clinical Trials
Most-Cited Works
- → Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation(2011)285 cited
- → Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response(2019)154 cited
- → Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation(2009)148 cited
- → Research methods to change clinical practice for patients with rare cancers(2016)112 cited
- → Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year(2020)62 cited
- → Akute lebensbedrohliche Bradykardie: Nahrungsmittelintoxikation durch türkischen Waldhonig(2008)35 cited
- → Small sample sizes in clinical trials: a statistician’s perspective(2012)25 cited
- → Stratified medicine in European Medicines Agency licensing: a systematic review of predictive biomarkers(2014)19 cited
- → The Cancer Drugs Fund in Practice and Under the New Framework(2019)19 cited
- → Assessing the Quality and Coherence of Network Meta-Analyses of Biologics in Plaque Psoriasis: What Does All This Evidence Synthesis Tell Us?(2020)14 cited